Expansion of reimbursement for the combination of SGLT-2 diabetes treatment and other treatments is expected to be applied from April. It is said that the government accepted the wage increase after receiving details of voluntary reductions from related companies earlier this month.

According to the industry on the 20th, it was reported that the Ministry of Health and Welfare, which is discussing the expansion of the combined benefit of SGLT-2 diabetes treatment, has set up a plan to apply for the benefit in April. Currently, the concomitant benefit drugs being discussed are triple therapy such as metformin + SGLT-2 + DPP-4, metformin + SGLT-2 + TZD, and some SGLT-2 items + sulfonylurea or insulin combi